Pharmatech’s Biomarker Panel Focused on Patients and Keeping Companies Ahead of the Curve

April 8, 2014 - PRLog -- Pharmatech announced its first Biomarker Panel round table entitled: “Development of Oncology Clinical Trials in the Time of Precision, Personalized Medicine,” that will be held on May 15, in Southern San Francisco.

The focus of the meeting will be on the changing industry standards and how companies can stay ahead of the oncoming advancements of precision cancer medicine. The previous method of screening many patients to find one specific biomarker is becoming obsolete. Pharmatech and its partners, Paradigm and Imaging Endpoints, are working to focus the trials on cancer patients’ efficiency and convenience and in turn accelerating the patient number aligned to clinical trials.

The panel will feature industry focused professionals including: Dr. Linda Strause, Dr. Ron Korn, Dr. Robert Penny and Rob Bohacs.

Dr. Strause is the Principal at Strategic Clinical Consultants and has over 25 years of expertise in global clinical operations and clinical development, with emphasis in oncology and ethical considerations for subjects with life-threatening disease. She is considered an expert in oncology programs as well as metabolic bone disease including Phase I through III studies and was most recently honored by ACRP as the Top Speaker for 2013.

Dr. Penny is the Founder and the CEO of Paradigm, a cutting-edge advanced diagnostics company specializing in personalized medicine. He created and directly impacted the success of IGC’s national Expression Project for Oncology (expO). The College of American Pathologists awarded Dr. Penny the national organization’s 2012 Distinguished Patient Care Award for his extensive scientific translational research to accelerate the adoption of molecular pathways and associated therapies.

Dr. Korn is the Founder, CEO, and Medical Director at Imaging Endpoints and one of its most recognized board-certified and fellow-ship train radiologists. Dr. Korn specializes in Nuclear Medicine and Cancer Biology and received the Top Doctor Award for Radiology and Nuclear Medicine. He also presented at the 12^th Annual World Pharma Congress last year, held in Pennsylvania.

Mr. Bohacs, the CEO of Pharmatech, is an expert in healthcare informatics. He has lead multiple highly disruptive innovation, efficacy driven technology solutions in healthcare and carries his expertise into the clinical research environment. Mr. Bohacs joined Pharmatech seven years ago and held several senior level positions prior to taking the lead role within the organization.

Pharmatech, headquartered in Denver, Colorado, is an oncology focused Contract Research Organization (CRO) and Site Management Organization (SMO). Through an organized network of cancer clinics, the company focuses on accelerating the development of products for a broad range of pharmaceutical and biotechnology companies, and promoting the inclusion of clinical trials in the spectrum of patient treatment options.